MedTrace Logo

Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

NCT03290560 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2022-03-31

No results posted yet for this study

Summary

This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Recombinant human tissue kallikrein

Recombinant human tissue kallikrein

OTHER

Placebo

Placebo Comparator: Phosphate buffered saline

Sponsors & Collaborators

  • DiaMedica Therapeutics Inc

    lead INDUSTRY

Principal Investigators

  • Bruce Campbell · Melbourne Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-19
Primary Completion
2020-01-23
Completion
2020-01-23

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03290560 on ClinicalTrials.gov